AK137 for advanced tumors that have stopped responding to standard treatments
Part of Cancer, Immune system & allergy clinical trials.
This phase 1 trial tests a new drug called AK137, which is designed to help your immune system better attack cancer cells. It is for people with advanced tumors that have not been helped by standard therapies. The goal is to find out if AK137 is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced or metastatic solid tumor that standard treatments have not helped or that you cannot tolerate.
- You are well enough to be up and about (able to take care of yourself but not able to do heavy physical work).
- Your doctor expects you to live at least 3 more months.
- You have at least one tumor that can be measured on a scan.
- Your organs (like kidneys, liver, and bone marrow) are working well enough, as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and early anti-cancer activity of AK127 given together with AK104 in people with advanced solid tumors. You may be considered if standard treatments have already been tried or aren’t suitable for you.
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial tests a new drug called AK131 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and can help slow or shrink the cancer.
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
This trial tests a new drug called AK138D1 for people with advanced solid tumors that have not responded to or can't tolerate standard treatments. The goal is to see if it is safe and effective.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.